

SeqOne Genomics Raises €20 Million in Oversubscribed Growth Round to Lead AI-Powered NGS Revolution in Personalized Medicine

New capital from Supernova Invest, alongside existing partners Elaia, Omnes, and Merieux Equity Partners, will accelerate SeqOne's mission to transform genomic diagnostics worldwide, focusing on international expansion, U.S., and strategic growth.

MONTPELLIER, France – May 22, 2025 – SeqOne, a pioneer in AI-driven genomic analysis for personalized medicine, today announced a significant €20 million oversubscribed growth funding round. Led by new investor Supernova Invest, with robust continued support from existing major investors Elaia, Omnes, and Merieux Equity Partners, this capital injection will fuel SeqOne's global expansion and solidify its leadership in transforming patient care through advanced genomic insights.

This latest investment will be pivotal in SeqOne's mission to establish itself as the European champion in Next-Generation Sequencing (NGS) data analysis and interpretation for clinical diagnostics, with a clear ambition to become the world-leading software in this dynamic field, where the demand for precise and scalable genomic interpretation is accelerating globally. The financing also places SeqOne in a strong financial position, reinforcing its commitment to being a reliable, long-term partner for its customers.

This funding will accelerate SeqOne's strategic growth across three core pillars:

- **Global Expansion:** Scale international operations further, building on significant momentum (3x customer growth to 140 labs in 22 countries in 12 months, over 110,000 patient analyses in 2025).
- **U.S. Market Acceleration:** Intensifying U.S. operations following Q1 2025 market entry with SeqOne's U.S.-dedicated, HIPAA-compliant platform.
- **Strategic Acquisitions:** Continuing to pursue targeted acquisitions to expand capabilities and market share, such as the recent Life & Soft acquisition for its multi-omics expertise.

"This fundraising is a testament to the incredible work of our team and the transformative potential of our platform in making personalized medicine a reality," said Martin Dubuc, CEO of SeqOne. "We are thrilled to welcome Supernova Invest and are deeply grateful for the continued trust of Elaia, Omnes, and Merieux Equity Partners. This new capital injection not only empowers us to scale our international operations, particularly with our US launch, and to further enhance our technological leadership, but it also fortifies our financial foundations, ensuring our customers can depend on us as a steadfast partner for years to come. Our goal is to equip every molecular laboratory with the most advanced, intuitive, and reliable genomic analysis solutions."

Rémi Spagnol, Investment Director at Supernova Invest, commented, "SuperNova Invest is proud to partner with SeqOne, a company at the forefront of genomic analysis innovation. Their impressive growth, cutting-edge technology, and visionary leadership team give us strong conviction in their ability to become a global category leader. The market needs modern, automated, scalable solutions, and SeqOne is exceptionally well-positioned to meet this demand. We are excited to support their journey in revolutionizing how genetic data is used to improve patient outcomes and to help them build a true European champion with global reach."

About SeqOne

SeqOne is a deep-tech company committed to making personalized medicine a reality. Its AI-powered genomic analysis platform provides clinical decision-support tools that enable molecular laboratories to deliver fast, accurate, and scalable analysis of genetic data for applications in oncology, rare diseases, and, through recent acquisitions, multi-omics, including pathogen detection. With 140 active lab customers across 22 countries and a projection to process over 110,000 patient analyses in 2025, SeqOne serves a growing global customer base of healthcare providers and biopharmaceutical companies, supported by strong industry partnerships and an expanding presence in the US market. www.seqone.com

About Supernova Invest

Supernova Invest is the leading deeptech Venture Capital firm in Europe and manage c.€800 million in assets. The current portfolio includes 80+ innovative and impact-driven companies that develop products and services leveraging breakthrough technologies in 4 transition-centric sectors: Cleantech, Digital, Industrial Technologies and Healthcare. For 20 years, Supernova Invest has been providing long-term capital, operating experience, and strategic support to back sustainable growth of tomorrow's deep tech and industrial champions throughout the Venture Capital life cycle: seed, early, late and growth stages. Supernova Invest also gathers the entire deep tech value chain to support portfolio companies: corporates, research institutions and co-investors.

Supernova Invest is backed both by Amundi, the largest asset manager in Europe, and CEA, the most innovative public research organization in Europe. www.supernovainvest.com

About Elaia

Elaia is a European full stack tech and deep tech investor. We partner with ambitious entrepreneurs from inception to leadership, helping them navigate the future and the unknown. For over twenty years, we have combined deep scientific and technological expertise with decades of operational experience to back those building tomorrow. Our joint venture with Lazard, Lazard Elaia Capital, enables us to support exceptional founders at any stage. From our offices in Paris, Barcelona and Tel Aviv, we have been active partners with over 100 startups including Criteo, Mirakl, Shift Technology, AQEMIA and Alice & Bob. Learn more at elaia.com.

About Omnes

Omnes is a leading private equity firm dedicated to energy transition. With over €6.7 bn in assets under management, our teams support long-term partnerships with entrepreneurs through our four core businesses: renewable energy, sustainable cities, deeptech and co-investment. For over 20 years, Omnes has been applying its expertise to help businesses grow in more than 15 countries, with a particular focus on sustainable development. As part of its approach as a responsible investor, the company has created the Omnes Foundation to support non-profit organisations working for children and young people in the fields of education, health, social and economic integration. www.omnescapital.com

Media contacts:

SeqOne Madeleine Latapie | madeleine.latapie@seqone.com

Supernova Invest Asmae Zahrathaddi Benfella | Asmae.benfella@vae-solis.com 06 63 30 86 41

Omnes Capital Estelle Eonnet | estelle.eonnet@omnescaptal.com +33 7 55 59 38 62